Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.95 -5.2%	$4.72	$1.00 ▼ $7.00	$46.29M	0.67	154,969 shs	15,795 shs
ATNM Actinium Pharmaceuticals	$1.65 -3.5%	$1.58	$1.03 ▼ $2.41	$51.47M	-0.53	420,074 shs	96,492 shs
ERNA Ernexa Therapeutics	$1.55 -3.7%	$1.95	$1.50 ▼ $28.80	$12.35M	5.42	78,140 shs	28,085 shs
TELO Telomir Pharmaceuticals	$1.47 -1.3%	$1.65	$1.12 ▼ $8.40	$48.10M	-0.67	751,511 shs	128,880 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+0.19%	-1.88%	+4.40%	+24.29%	+275.54%
ATNM Actinium Pharmaceuticals	+1.18%	+16.33%	0.00%	-6.56%	-6.04%
ERNA Ernexa Therapeutics	+1.58%	-3.54%	-18.69%	-55.15%	-93.76%
TELO Telomir Pharmaceuticals	0.00%	-5.70%	-34.65%	-34.93%	-62.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.972 of 5 stars	3.3	5.0	3.3	1.7	0.0
ATNM Actinium Pharmaceuticals	2.9331 of 5 stars	3.5	5.0	2.8	0.0	0.6
ERNA Ernexa Therapeutics	0.4211 of 5 stars	0.0	3.0	1.6	1.7	0.0
TELO Telomir Pharmaceuticals	2.4606 of 5 stars	3.8	2.0	1.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	142.42% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	172.73% Upside
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	920.41% Upside

Current Analyst Ratings Breakdown

Latest ERNA, ATHE, ATNM, and TELO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
ERNA Ernexa Therapeutics	$580K	20.50	N/A	N/A	$0.58 per share	2.67
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	0.00	∞	N/A	-7,652.75%	N/A	-682.08%	N/A
TELO Telomir Pharmaceuticals	-$16.53M	-$0.54	0.00	N/A	N/A	N/A	-4,595.08%	-1,750.91%	N/A

Latest ERNA, ATHE, ATNM, and TELO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TELO Telomir Pharmaceuticals	-$0.08	-$0.17	-$0.09	-$0.17	N/A	N/A
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
ERNA Ernexa Therapeutics	N/A	1.81	1.81
TELO Telomir Pharmaceuticals	N/A	2.39	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
ATNM Actinium Pharmaceuticals	27.50%
ERNA Ernexa Therapeutics	70.55%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
ATNM Actinium Pharmaceuticals	6.00%
ERNA Ernexa Therapeutics	4.49%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
ERNA Ernexa Therapeutics	10	7.67 million	7.33 million	No Data
TELO Telomir Pharmaceuticals	1	32.28 million	N/A	N/A

ERNA, ATHE, ATNM, and TELO Headlines

Recent News About These Companies

TELO Makes Progress Toward Human Trials

August 15, 2025 | msn.com

Telomir-1 inhibits key histone demethylase enzymes in vitro

August 12, 2025 | bioworld.comB

Telomir Pharmaceuticals (TELO) Projected to Post Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8, 2025 | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 5% - Here's What Happened

July 23, 2025 | marketbeat.com

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ERNA, ATHE, ATNM, and TELO Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$4.95 -0.27 (-5.17%)

Closing price 03:59 PM Eastern

Extended Trading

$5.01 +0.06 (+1.21%)

As of 07:36 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Actinium Pharmaceuticals NYSE:ATNM

$1.65 -0.06 (-3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.63 -0.02 (-1.21%)

As of 06:04 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Ernexa Therapeutics NASDAQ:ERNA

$1.55 -0.06 (-3.73%)

Closing price 03:59 PM Eastern

Extended Trading

$1.62 +0.07 (+4.52%)

As of 06:21 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.47 -0.02 (-1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 0.00 (0.00%)

As of 07:58 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time